Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)

Launched by FUNDACION CLINIC PER A LA RECERCA BIOMÉDICA · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the presence of the corpus luteum, a structure formed in the ovary after an egg is released, affects pregnancies achieved through frozen embryo transfer (FET). Researchers want to find out if there are differences in various health aspects, such as how the blood vessels and placenta function, as well as the growth and development of the baby, depending on whether the corpus luteum is present during the pregnancy. They will also look at how certain substances produced by the corpus luteum might relate to these differences.

To participate in this study, women aged 18 to 37 who have regular menstrual cycles and have frozen embryos from their own eggs may be eligible. It's important that they are planning for a single embryo transfer and do not have certain health conditions, like polycystic ovarian syndrome or a history of multiple unsuccessful embryo transfers. Participants can expect to undergo either a programmed or modified natural frozen embryo transfer, and the trial aims to improve understanding of factors that contribute to successful pregnancies in these situations.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients 18- 37 years old (both included) at the time of oocyte retrieval and less than 41 years of age at the time of embryo transfer.
• • Regular menstrual cycles between 24 and 35 days.
• • Availability of cryopreserved blastocysts from own gametes
• • Indication for single embryo transfer.
• • Patients who will be included in the LUTI study are candidates for either of the two procedures under study, and will have no contraindications for either procedure.
• Exclusion Criteria:
• • Recurrent pregnancy loss (3 or more).
• • Recurrent implantation failure in previous IVF treatments (3 or more unsuccessful embryo transfers). .
• • Diagnosis of polycystic ovarian syndrome, diabetes mellitus, chronic arterial hypertension, maternal heart disease and autoimmune diseases (Systemic Lupus Erythematosus (SLE) or Antiphospholipid syndrome (APS)).
• • Active treatment with aspirin, heparin or other anticoagulant therapy, antihypertensives or other drugs used to treat circulation or coagulation disorders .
• • Indication for PGT (Preimplantation Genetic Testing).
• • Multiple pregnancy.